BDTX 株価推移チャート
BDTX 財務
Black Diamond Therapeutics Inc
$1.7
-8.6%
$-0.16
終値： Jun 25, 16:00:00 GMT-4
$1.73
2.25%
$0.03
アフターマーケット：Jun 25, 20:00:00 GMT-4
戻る
Black Diamond Therapeutics Inc (BDTX) 財務
主要データ
前終値
$1.86
始値
$1.86
当日レンジ
$1.69 - $1.89
52週レンジ
$1.73 - $4.94
取引高
1.9M
平均取引高
1.0M
配当利回り
--
1株当たり利益(TTM)
-0.76
時価総額
$99.6M
BDTXとは何ですか？
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
